Iran's local vaccine CovPars inches closer to market amid surge in COVID cases
Yusef Jalali
Press TV, Karaj
Among the seven Iranian COVID vaccines, CovPars is making a name for itself. Developed by Razi Serum and Vaccine Research Institute, the recombinant vaccine started the third human trial phase on Sunday.
Iran has so far vaccinated roughly 10 percent of its population. This as the resurgence of the coronavirus in more lethal forms, like the delta variant, has been killing an average of around 500 Iranians every day in the past month.
As the government is scrambling to import more vaccines, CovPars authorities say they are working to get an emergency use license to help speed up the inoculation program.
CovPars is administered in three doses; two intramuscular shots 21 days apart and one intranasal shot one month after the second dose. The third phase is expected to take six months.
As the coronavirus keeps transforming into wilder variants with an unprecedented rate, CovPars developers say they have already launched the production line to accelerate vaccinations.
The biotech firm says as soon as it gets the emergency use license, it will kick off mass production with the capacity of 3 mn doses per month.
Pres. Raeisi says Iran, Pakistan resolved to boost ties on all levels
Syrian, Palestinian officials hail Iran's operation against Israel
French ban on anti-Islamophobia protest fails amid mounting state repression
Google fires more employees over anti-Israel protests
Iran set to build more nuclear power plants: AEOI chief
'Iran’s True Promise ushers in new era for region; strategic implications felt across globe'
VIDEO | Arrest and harassment: US intensifies crackdown on pro-Gaza protests in universities
VIDEO | Press TV's news headlines
France fails to ban anti-Islamophobia protests
In Numbers: 200 days of Israeli genocidal war against Palestinians in Gaza
Death toll mounts in Gaza as Israeli genocidal war marks 200 days
This makes it easy to access the Press TV website
